| Name | Title | Contact Details |
|---|
Bringing Great Designs Home. B2B - Shop our Retailers! Window • Flooring • Home Accessories
Our job is to make you more successful. From streamlined, optimized reports, to crisp websites which convert visitors into customers! We are the future of home inspection software. Fast. Detailed. Accurate. Property Inspection Reports for Android. Webs...
Showa Denko Carbon, Inc. is a Ridgeville, SC-based company in the Business Services sector.
Unicom Teleservices is a Blue Island, IL-based company in the Business Services sector.
CARB-X (Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator) is a global non-profit partnership dedicated to accelerating early development antibacterial R&D to address the rising global threat of drug-resistant bacteria. CARB-X is led by Boston University and its funding is provided by the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response (ASPR) in the U.S. Department of Health and Human Services; the Wellcome Trust, a global charity based in the UK; Germanys Federal Ministry of Education and Research (BMBF); the UK Department of Health and Social Cares Global Antimicrobial Resistance Innovation Fund (UK GAMRIF); the Bill & Melinda Gates Foundation, and with in-kind support from National Institute of Allergy and Infectious Diseases (NIAID), part of the US National Institutes of Health (NIH) within the HHS. CARB-X is investing more than $500 million from 2016-2021 to support innovative antibiotics and other therapeutics, vaccines and rapid diagnostics. CARB-X supports the worlds largest and most innovative pipeline of preclinical products against drug-resistant infections. CARB-X focuses exclusively on high priority drug-resistant bacteria, especially Gram-negatives. CARB-X is headquartered at Boston University School of Law.